📣 Two months ago, we proudly kicked off our San Francisco State University Mentorship Program for 2025. Today, we celebrate the incredible journey shared with our enthusiastic cohort of STEM students. 🚀 Thank you to our mentees for your innovative ideas and energy, and to our mentors for sharing your knowledge and experience. Here's to impacting patients’ lives together! #STEM #SFSU
Vir Biotechnology, Inc.
生物技术研究
San Francisco，California 34,451 位关注者
Powering the Immune System to Transform Lives
关于我们
At Vir Biotechnology, Inc., we leverage the immense potential of the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. We focus on the therapeutic areas in which we believe we can most benefit patients. Our foundational efforts in infectious diseases, with leading programs in chronic hepatitis delta and chronic hepatitis B, are complemented by strategic programs in oncology. Every day, we work with the utmost urgency to deliver potentially transformative medicines for patients. Our pipeline is built on two technology platforms which enable us to rapidly identify, optimize and advance candidates from concepts to the clinic: our next-generation antibody platform and our protease-releasable masking platform in infectious disease and cancer. Explore our full pipeline here: https://bit.ly/3tr7FPm It has come to our attention that there have been various recruitment scams targeting job seekers on LinkedIn. Vir Biotechnology, Inc. is committed to your privacy and will never request sensitive personal information including banking details through email, text message, social media or video software platforms. We also will never request a financial commitment from a candidate as part of the application process. Learn more about Vir’s recruiting process: https://bit.ly/461EgJN
- 网站
-
http://www.vir.bio
Vir Biotechnology, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 201-500 人
- 总部
- San Francisco，California
- 类型
- 上市公司
- 创立
- 2016
地点
Vir Biotechnology, Inc.员工
动态
-
💡We are shining a light on some of our incredible leaders who drive scientific innovation, inspire teams and steer the future of #VirBiotechnology. We’re proud and grateful to be #MovingForwardTogether with them! Learn about our broader leadership team here ➡️ https://bit.ly/427dnn9
-
📣Check out #VirBiotechnology on the iconic NASDAQ MarketSite Tower in the heart of Times Square shining a spotlight on the initiation of our Phase 3 ECLIPSE Registrational Program in chronic hepatitis delta! People living with hepatitis delta need transformational treatment now. We are excited to be edging closer every day to delivering on our mission of powering the immune system to transform lives. Read more here ➡️ https://bit.ly/41NZHx1 #PatientsAreWaiting #HepatitisD #NASDAQ
-
-
"Patients are waiting for safe and effective treatment, so as an industry it is our responsibility to develop a medicine as efficiently as possible to enable long-term use for patients. Never has it been more urgent to get this right than in hepatitis delta where there are no approved treatments in the U.S. and on average patients progress to cirrhosis and liver transplant in five years." Our Chief Medical Officer Mark Eisner, spoke at #REpharmaUSA this week, exploring how to best accelerate clinical development in partnership with key stakeholders. Mark shared our progress in expediting our ECLIPSE registrational program in hepatitis delta which has now begun enrolling patients. #PatientsAreWaiting #HepatitisD #Immunology
Mark Eisner (Vir Biotechnology, Inc.) shares how partnerships should be leveraged to innovate with agility and speed to outpace competitors in bringing forward therapeutics that address areas of greatest unmet patient need. Thanks for joining us, Mark! #REpharmaUSA
-
-
📢 Phase 3 ECLIPSE Registrational Program in Chronic Hepatitis Delta Initiated 📢 People living with chronic hepatitis delta face significant unmet needs, as there is no approved treatment in the U.S., and options are limited in the European Union and globally. At #VirBiotechnology, we are working to change that. The start of the ECLIPSE registrational program is an important step forward on our path to delivering a highly effective treatment for people living with chronic hepatitis delta. Read more here ➡️ https://bit.ly/41NZHx1 #HepatitisD #PatientsAreWaiting
-
-
Virites showed their support for #IWD2025 this week and called for us all to #AccelerateAction💪. Let’s continue to support and empower women to achieve their goals in #STEM and drive meaningful change together!
-
-
Congratulations to our CEO Marianne D. De Backer, MSc, PhD, MBA for her insightful discussion with fellow Biotech CEO, Grace Colón, as part of the Biotech CEO Sisterhood on BiotechTV. Marianne shared her journey to #VirBiotechnology, how her diverse experiences have shaped her leadership style, and how she’s implementing these learnings in service of our mission of powering the immune system to transform lives. #PatientsAreWaiting
𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐂𝐄𝐎 𝐒𝐢𝐬𝐭𝐞𝐫𝐡𝐨𝐨𝐝: Vir Biotechnology, Inc.'s CEO Marianne D. De Backer, MSc, PhD, MBA describes her background and leadership style, and joining Vir as it experienced a road bump, but turning it into an opportunity via a key IO deal. Interviewed by Biotech CEO Sisterhood editorial board member Grace Colón, Marianne De Backer advocates for the importance of getting experience in a diverse set of roles, she describes joining Vir at a time when it had experienced its first setbacks, and how a deal for a T-cell engager program has been transformational. Full video: https://lnkd.in/g2RkKye8 BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | Klein Hersh | Savills
-
As we take a look back at this #BlackHistoryMonth, we want to extend a huge thank you to Studio 5 - Learning and Development, Inc. for hosting an insightful discussion about the powerful contributions of Black and African American people throughout history, which include groundbreaking achievements in science. At #VirBiotechnology, we cherish these learning moments that enrich our understanding and commitment to inclusivity.
-
📢#VirBiotechnology News: Today our Chief Executive Officer Marianne D. De Backer, MSc, PhD, MBA shares our Q4 and Full Year 2024 financial results. As we enter 2025, we are poised for significant advancement: https://bit.ly/3QBPWgh #Earnings
-
👉#VirBiotechnology will provide a corporate update and report Q4 and Full Year 2024 financial results on Wed., Feb. 26, at 1:30 p.m. PT/4:30 p.m. ET. Join us for our investor conference call to hear about our progress in 2024 and potential for significant advancement in 2025. https://bit.ly/3XgaQ8m #Earnings